Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

Part of paid clinical trials in Tampa, Florida.

Sponsor
University of South Florida
Study ID
NCT02932007
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Chloroquine Phosphate — DRUG
    Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.

Study Details

The goal of this pilot study is to explore the efficacy of chloroquine in terminating persistent AF and assess its potential role as a pharmacological cardioversion agent for the management of AF.

Key Dates

Start date
Mar 28, 2017
Status verified
Oct 2018
Primary completion
Mar 31, 2020
Completion
Sep 30, 2020

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Chloroquine Phosphate
    Chloroquine Phosphate will be provided at 500 mg dosage strength for oral administration. Patient will be instructed to take 2 tablets per day on the first two days and 1 tablet each day for the next 12 days for a total of 14 days treatment.

Primary Outcome Measure

Proportion of patients with termination of AF [ Time Frame: Within 2 weeks of study drug initiation ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of South FloridaTampaFlorida33606
Nhi Tran, MS
[email protected]
813-259-0628
Jacob Siddoway
[email protected]
Sami Noujaim, PhD (PRINCIPAL_INVESTIGATOR)
Bengt Herweg, MD (SUB_INVESTIGATOR)
Dany Sayad, MD (SUB_INVESTIGATOR)

Find similar trials in Tampa, FL

By condition
Atrial fibrillation
By specialty
CardiologyHeart disease
By research site
University of South Florida· Tampa, FL

Related Studies